

B

Annual Report 2020

Contact Information

BC Centre for Disease Control Clinical Prevention Services 655 West 12th Avenue Vancouver, BC, V5Z 4R4

Phone: 604-707-2400 Fax: 604-707-5604

Email: CPSSurveillance@bccdc.ca

Date of publication: February 1, 2023 Report is available at www.bccdc.ca

Suggested citation: BC Centre for Disease Control. TB in British Columbia: Annual Surveillance Report 2020 [Internet]. 2023. Available from: http://www.bccdc.ca/health-professionals/data-

reports/tuberculosis-reports/



020 Summary of Trends

Summary of Trends

All TB surveillance data comes from Panorama Public Health Solution for Disease Surveillance and Management, unless otherwise noted. TB Services commenced using Panorama on March 12, 2016, with data conversion from the previous Integrated Public Health Information System (iPHIS). Minor differences in the aggregate counts may be seen if comparing annual report data to that found in iPHIS due to data conversion from iPHIS to Panorama. Numbers in this report are subject to change due to data clean up and possible late reporting.

Active TB

- In 2020, the rate of active TB in BC was 6.1/100,000 population (315 cases), down slightly from 6.2/100,000 population (314 cases) in 2019.
- Regional rates of active TB in 2020 were greatest in the Fraser Health Authority (9.0/100,000 population; 174 cases) and the Vancouver Coastal Health Authority (8.5/100,000 population; 105 cases).
- Males had a higher active TB rate (6.6/100,000 population; 168 cases) than females (5.6/100,000 population; 147 cases) in 2020.
- TB rates among males and females were generally greater in older age groups.
- In 2020, 83.5% (263 cases) of all active TB cases were among individuals born outside of Canada. Among this group, the active TB rate was 17.5/100,000 population.
- In 2020, 75.2% (237 cases) of active TB cases had known HIV status (either through lab report or self-report of HIV diagnosis), an increase from 72.3% (227 cases) in 2019. Of those with known HIV status, 1.3% (3 cases) had HIV infection, down slightly from 1.8% (4 cases) in 2019.
- The majority of active TB cases (80.3%, 253 cases) had at least one respiratory site involved with their active disease in 2020.
- Drug resistant active TB is a concern worldwide, and while rates of isoniazid-resistant TB were generally decreasing in BC since 2015, they began to increase again following 2017. In 2020, 7.3% (23 cases) of all active TB cases had isoniazid resistance, up from 6.7% (21 cases) in 2019. Two cases of multi-drug resistant TB (i.e. resistance to both isoniazid and rifampin) were seen in 2020 (0.6%), similar to 2019.

Latent TB Treatment

- A total of 766 individuals were started on latent TB infection (LTBI) treatment in 2019, of which 75.8% (581 clients) successfully completed treatment within 12 months and 0.3% (2 clients) took longer than 12 months to complete treatment.
- Of those starting LTBI treatment, 23.9% (183 clients) were documented with incomplete treatment in 2019.

2020 Summary of Tren

• LTBI treatment is more commonly reported among those born outside of Canada and those 40 years of age and older.

Contact Tracing

- In 2020, a mean of 5.1 contacts (median= 3.0) were documented per respiratory active TB case.
- Among contacts of respiratory active TB cases aged 5 years and older in 2019 (2154 contacts), 88.3% (1903 contacts) completed an initial assessment, 0.6% (14 contacts) were identified as secondary cases, 15.5% (334 contacts) screened positive, and 5.8% (125 contacts) successfully completed LTBI treatment.

Active TB

Active TB Historical Trends

In BC, the rate of active TB slightly decreased to 6.1/100,000 population (315 cases) in 2020, down from 6.2/100,000 population (314 cases) in 2019 (Table 2; Figure 1). Overall, the rate of active TB in BC has been between 6.0 and 6.2 per 100,000 population since 2015, with the exception of 2016. Despite the emergence of COVID-19 in 2020 – and the associated public health restrictions – provincial rates of active TB did not appear to have been impacted by the pandemic in BC. Similarly, the rate of active TB in Canada has stayed generally stable over the past decade and in 2020 the national rate was 4.7/100,000 population. Compared to the Canadian rate, the active TB rate in BC has remained consistently higher. Stable rates of active TB highlight the need for ongoing public health strategies to reduce the burden of TB and that support the provincial and national milestones for the reduction of morbidity and mortality related to TB.

Active TB by Health Authority of Residence

In 2020, the rate of active TB was highest in Fraser Heath Authority (FHA; 9.0/100,000 population, 174 cases), followed by Vancouver Coastal Health Authority (VCHA; 8.5/100,000 population, 105 cases), Northern Health Authority (NHA; 3.0/100,000 population, 9 cases), Interior Health Authority (IHA; 1.7/100,000 population, 14 cases), and Vancouver Island Health Authority (VIHA; 1.5/100,000 population, 13 cases). The rate of active TB in NHA and VIHA decreased in 2020 compared to 2019, while FHA, IHA, and VCHA all showed an increase (Table 4; Figure 2). Accordingly, the highest rates of active TB at the Health Service Delivery Area level were observed within FHA (Fraser East, Fraser North, Fraser South) and VCHA also (Richmond, Vancouver, North Shore/Coast Garibaldi) (Figure 3).

Active TB by Gender and Age

The rate of active TB has been historically higher in males than in females. In 2020, the active TB rate in males was 6.6/100,000 population (168 cases) compared to 5.6/100,000 population (147 cases) in females (Table 6; Figure 4). Relative to 2019, these rates slightly decreased among males and females in 2020. Active TB rates among females and males were generally greater in older age groups, which has been a consistent trend (Table 8; Figure 5; Figure 6). While rates of active TB have been historically low in the youngest age groups, since 2018 rates increased most notably among females 10-19 years of age up to 5.5/100,000 population in 2020. Active TB disease in those <5 years of age indicates recent transmission because of the

low probability of historic exposure and reactivation. There were two cases of active TB diagnosed in those <5 years of age in 2020 (Table 7).

Active TB by Country of Birth

In BC in 2020, 83.5% (263 cases) of active TB cases occurred in those born outside of Canada, a decrease from 84.1% (264 cases) in 2019 (Table 10; Figure 8). This corresponds to a rate of 17.5/100,000 population in 2020, down slightly from 17.9/100,000 population in 2019 (Table 11; Figure 9). Rates of active TB were greatest among those born outside of Canada across all health authorities (Table 13; Figure 11). Of the cases born outside of Canada in 2020, 40.7% (107 cases) were 60 years of age and older, 33.5% (88 cases) were 20-39 years of age, and 19.8% (52 cases) were 40-59 years of age (Table 17; Figure 13). Of all active TB cases in 2020, 15.6% (49 cases) were born in Canada, a small increase from 15.0% (47 cases) in 2019 (Table 10; Figure 8). In 2020, the rate of active TB among Canadian born cases was 1.5/100,000 population as was seen in 2019 (Table 11; Figure 9). See Data Sources for more information on how rates were calculated.

Many of BC's recent immigrants come from regions with high rates of active TB such as the South East Asia and Western Pacific regions as defined by the World Health Organization. ⁴ Active TB among individuals born outside of Canada appears to result largely from reactivation of latent TB infection, and local transmission is generally low. ⁵ Immigration, Refugees and Citizenship Canada (IRCC) currently screens immigrants applying for permanent residency for active TB, as well as all students, visitors or workers staying for more than 6 months. Visitors, students, or workers staying less than 6 months do not undergo routine screening mandated by IRCC.

Active TB by HIV Status

In 2020, 75.2% (237 cases) of active TB cases had known HIV status (either through lab report or self-report of HIV diagnosis), an increase from 72.3% (227 cases) in 2019 (Table 19; Figure 14). Over the preceding decade, less than 5% of active TB cases with known HIV status were coinfected with HIV. Of those with known HIV status, 1.3% (3 cases) had HIV infection in 2020, down slightly from 1.8% (4 cases) in 2019.

Active TB by Site of Disease

The site of active TB describes the primary clinical location of TB disease. Respiratory disease is generally more transmissible than non-respiratory disease. Of the active TB reported in BC in 2020, 80.3% (253 cases) were respiratory cases, which is within historic trends (Table 21; Figure 15).

Active TB by Treatment Outcome

Treatment outcomes are reported for active TB cases diagnosed in 2019 owing to the long duration of active TB treatment, and exclude post-mortem diagnoses (2 cases in 2019). Of those diagnosed with active TB in 2019 (312 cases), 98.7% (308 cases) were documented to have started treatment (Table 23; Figure 16). There were 4 cases (1.3%) with no treatment documented in 2019, with three of these cases having died before treatment was initiated and one that was lost to follow-up (Table 22).

Among diagnosed active TB cases, 80.1% (250 cases) successfully completed active TB treatment, with the majority (65.4%, 204 cases) completing treatment within 12 months and 14.7% (46 cases) taking longer than 12 months to complete (Table 23; Figure 16).

Among active TB cases with incomplete treatment (41 cases) – excluding those cases that left BC during treatment – the majority (48.8%, 20 cases) died during treatment, 24.4% (10 cases) were lost to follow-up, 12.2% (5 cases) had an unspecified reason (i.e. "Other"), 9.8% (4 cases) had a drug reaction/intolerance, 2.4% (1 case) were non-adherent, and 2.4% (1 case) had an unknown reason (Table 25; Figure 17).

Of those with incomplete treatment because they died during treatment (20 cases), 9 cases (22.0%) were documented with TB contributing to, but not being the underlying cause of death, 9 cases (22.0%) had a cause of death unrelated to their TB disease, one case (2.4%) had an underlying cause of death related to their TB disease, and one case (2.4%) had an unknown cause of death. Generally, mortality during active TB treatment has decreased from 2011 to 2019.

Active TB Drug Resistance

Drug resistant active TB is an important public health issue globally that can lead to lengthier, more complex, and more expensive treatment regimens. For this reason, provincial surveillance is essential. In 2020, isoniazid resistance was 7.3% (23 cases), up from 6.7% (21 cases) in 2019 (Table 27; Figure 19). Only 0.6% of cases (2 cases) in 2020 had multi-drug resistance (i.e. resistance to both isoniazid and rifampin), no change from 2019 (Table 26; Figure 18).

Active TB Historical Trends

Table 1. Active TB Cases in BC, 2011 to 2020


Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
ВС	279	299	281	305	288	255	308	303	314	315

Table 2. Active TB Rates* in BC and Canada, 2011 to 2020

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
ВС	6.2	6.5	6.1	6.5	6.0	5.2	6.2	6.0	6.2	6.1
Canada**	4.7	4.9	4.7	4.6	4.6	4.9	5.0	4.9	5.1	4.7

^{*}All rates are per 100,000 population

Figure 1. Active TB Rates in BC and Canada, 2011 to 2020



^{**}Canadian rates from the Public Health Agency of Canada¹

Active TB by Health Authority of Residence

Table 3. Active TB Cases by Health Authority in BC, 2011 to 2020

Health Authority*	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Fraser (FHA)	134	122	139	143	125	128	152	164	166	174
Interior (IHA)	13	32	24	15	9	13	13	18	12	14
Northern (NHA)	17	14	12	10	14	10	5	8	14	9
Vancouver Coastal (VCHA)	101	106	96	125	124	95	121	97	99	105
Vancouver Island (VIHA)	14	25	10	12	16	9	17	16	23	13

^{*}Residence classified at time of case

Table 4. Active TB Rates by Health Authority in BC, 2011 to 2020

Health Authority*	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Fraser (FHA)	8.2	7.3	8.2	8.3	7.1	7.1	8.3	8.8	8.7	9.0
Interior (IHA)	1.8	4.5	3.4	2.1	1.2	1.7	1.7	2.3	1.5	1.7
Northern (NHA)	6.0	4.9	4.1	3.4	4.9	3.4	1.7	2.7	4.7	3.0
Vancouver Coastal (VCHA)	9.1	9.3	8.2	10.4	10.5	8.0	10.1	8.0	8.1	8.5
Vancouver Island (VIHA)	1.9	3.3	1.3	1.6	2.0	1.1	2.1	1.9	2.7	1.5

^{*}Residence classified at time of case

Figure 2. Active TB Rates by Health Authority in BC, 2011 to 2020





Figure 3. Active TB Rates by Health Service Delivery Area*+ in BC, 2020

Active TB by Health Service Delivery Area



^{*}Health Service Delivery Area determined at time of case

⁺Population denominators come from 2020 Population Estimates from BC Statistics

Active TB by Gender and Age

Table 5. Active TB Disease Cases by Gender in BC, 2011 to 2020

Gender	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Female	115	109	131	137	153	119	143	139	146	147
Male	164	190	150	168	135	136	165	164	168	168

Table 6. Active TB Rates by Gender in BC, 2011 to 2020

Gender	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Female	5.1	4.7	5.6	5.8	6.3	4.8	5.7	5.5	5.7	5.6
Male	7.3	8.4	6.5	7.2	5.7	5.7	6.8	6.6	6.7	6.6

Figure 4. Active TB Rates by Gender in BC, 2011 to 2020




Table 7. Active TB Cases by Gender and Age Group in BC, 2011 to 2020

Gender	Age Group	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
	<1 Year	0	1	1	0	1	1	0	0	0	0
	1-4 Years	0	1	1	4	1	1	1	0	1	2
	5-9 Years	2	1	2	0	1	2	0	0	0	0
Female	10-19 Years	2	5	5	2	5	4	7	5	11	14
	20-39 Years	40	29	35	40	35	42	45	40	47	48
	40-59 Years	33	39	31	41	42	17	30	41	21	27
	60+ Years	38	33	56	50	68	52	60	53	66	56
	<1 Year	0	0	1	0	0	0	1	0	1	0
	1-4 Years	2	1	1	1	1	1	3	2	0	0
	5-9 Years	1	0	2	0	0	0	2	0	1	0
Male	10-19 Years	4	6	5	8	5	4	8	3	7	7
	20-39 Years	36	32	27	33	23	28	32	50	44	51
	40-59 Years	51	59	44	50	43	44	41	37	32	43
	60+ Years	70	92	70	76	63	59	78	72	83	67

Table 8. Active TB Rates by Gender and Age Group in BC, 2011 to 2020

Gender	Age Group	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
	<1 Year	0.0	4.7	4.6	0.0	4.6	4.6	0.0	0.0	0.0	0.0
	1-4 Years	0.0	1.1	1.1	4.6	1.1	1.1	1.1	0.0	1.1	2.3
	5-9 Years	1.9	0.9	1.8	0.0	0.9	1.7	0.0	0.0	0.0	0.0
Female	10-19 Years	0.8	2.0	2.0	0.8	2.0	1.6	2.8	2.0	4.3	5.5
	20-39 Years	6.6	4.7	5.6	6.3	5.5	6.5	6.8	5.9	6.8	6.8
	40-59 Years	4.9	5.7	4.4	5.8	5.9	2.4	4.2	5.8	3.0	3.8
	60+ Years	7.4	6.2	10.2	8.7	11.4	8.4	9.3	8.0	9.6	7.9
	<1 Year	0.0	0.0	4.4	0.0	0.0	0.0	4.3	0.0	4.5	0.0
	1-4 Years	2.1	1.1	1.1	1.1	1.1	1.0	3.1	2.1	0.0	0.0
	5-9 Years	0.9	0.0	1.7	0.0	0.0	0.0	1.6	0.0	0.8	0.0
Male	10-19 Years	1.5	2.2	1.9	3.0	1.9	1.5	3.0	1.1	2.6	2.6
	20-39 Years	5.9	5.2	4.3	5.1	3.5	4.2	4.7	7.1	6.1	6.9
	40-59 Years	7.6	8.8	6.5	7.4	6.3	6.5	6.1	5.5	4.8	6.4
	60+ Years	15.2	19.2	14.1	14.7	11.8	10.6	13.6	12.1	13.5	10.5

Figure 5. Active TB Rates Among Females by Age Group in BC, 2011 to 2020





Figure 6. Active TB Rates Among Males by Age Group in BC, 2011 to 2020



Active TB by Country of Birth

Table 9. Active TB Cases by Country of Birth in BC, 2011 to 2020

Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Born Outside of Canada	204	216	221	247	245	211	259	269	264	263
Canadian Born	64	68	54	57	39	33	44	32	47	49
Missing*	11	15	6	1	4	11	5	2	3	3

^{*}Unknown or undocumented country of birth

Figure 7. Active TB Cases by Country of Birth in BC, 2011 to 2020




Table 10. Percentage of Active TB Cases by Country of Birth in BC, 2011 to 2020

Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Born Outside of Canada	73.1	72.2	78.6	81.0	85.1	82.7	84.1	88.8	84.1	83.5
Canadian Born	22.9	22.7	19.2	18.7	13.5	12.9	14.3	10.6	15.0	15.6
Missing*	3.9	5.0	2.1	0.3	1.4	4.3	1.6	0.7	1.0	1.0

^{*}Unknown or undocumented country of birth

Figure 8. Percentage of Active TB Cases by Country of Birth in BC, 2011 to 2020





Table 11. Active TB Rates by Country of Birth in BC, 2011 to 2020

Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Born Outside of Canada	16.2	16.8	16.9	18.5	17.9	15.1	18.2	18.6	17.9	17.5
Canadian Born	2.1	2.2	1.7	1.8	1.2	1.0	1.4	1.0	1.5	1.5

Figure 9. Active TB Rates by Country of Birth in BC, 2011 to 2020



Active TB by Country of Birth and Health Authority

Table 12. Active TB Cases by Country of Birth and Health Authority in BC, 2011 to 2020

Health Authority*	Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Fraser (FHA)	Born Outside of Canada	109	103	118	125	113	115	133	146	145	150
	Canadian Born	20	14	18	18	10	8	18	18	19	23
Interior (IHA)	Born Outside of Canada	6	6	14	7	8	10	12	13	11	10
, ,	Canadian Born	7	23	8	8	1	2	1	5	1	4
Northern	Born Outside of Canada	1	4	4	4	4	2	0	3	8	1
(NHA)	Canadian Born	15	10	8	5	9	7	5	3	6	7
Vancouver Coastal	Born Outside of Canada	82	93	80	103	110	78	106	93	87	93
(VCHA)	Canadian Born	15	6	15	22	13	13	13	4	11	11
Vancouver	Born Outside of Canada	6	10	5	8	10	6	8	14	13	9
Island (VIHA)	Canadian Born	7	15	5	4	6	3	7	2	10	4

^{*}Residence classified at time of case

Table 13. Active TB Rates by Country of Birth and Health Authority in BC, 2011 to 2020

Health Authority*	Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Fraser (FHA)	Born Outside of Canada	20.0	18.3	20.4	21.0	18.5	18.3	20.6	22.1	21.4	21.6
` ,	Canadian Born	1.9	1.4	1.7	1.7	0.9	0.8	1.7	1.7	1.7	2.1
Interior (IHA)	Born Outside of Canada	7.4	7.2	16.6	8.1	9.1	11.2	13.1	14.0	11.6	10.4
, ,	Canadian Born	1.1	3.7	1.3	1.3	0.2	0.3	0.2	0.8	0.2	0.6
Northern	Born Outside of Canada	3.9	15.2	14.9	14.7	14.5	7.1	0.0	10.3	27.2	3.3
(NHA)	Canadian Born	6.1	4.0	3.2	2.0	3.6	2.8	2.0	1.2	2.4	2.8
Vancouver Coastal	Born Outside of Canada	16.8	18.9	16.0	20.4	21.5	15.1	20.3	17.6	16.3	17.2
(VCHA)	Canadian Born	2.6	1.0	2.6	3.8	2.2	2.2	2.2	0.7	1.8	1.8
Vancouver	Born Outside of Canada	5.1	8.4	4.1	6.4	7.9	4.6	6.1	10.4	9.5	6.4
Island (VIHA)	Canadian Born	1.2	2.5	0.8	0.6	1.0	0.5	1.1	0.3	1.6	0.6

^{*}Residence classified at time of case

Figure 10. Active TB Rates Among Populations Born in Canada by Health Authority in BC, 2011 to 2020





Figure 11. Active TB Rates Among Populations Born Outside of Canada by Health Authority in BC, 2011 to 2020



Active TB Among Populations Born in Canada by Age


Table 14. Active TB Cases Born in Canada by Age Group, 2011 to 2020

Age Group	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<1 Year	0	1	2	0	1	1	1	0	1	0
1-4 Years	2	2	1	4	1	2	3	0	0	2
5-9 Years	2	1	2	0	0	2	2	0	0	0
10-19 Years	0	4	4	3	4	1	4	0	4	5
20-39 Years	13	18	8	14	8	8	14	6	9	10
40-59 Years	26	28	23	21	14	9	13	13	14	18
60+ Years	21	14	14	15	11	10	7	13	19	14

Table 15. Percentage of Active TB Cases Born in Canada by Age Group, 2011 to 2020

Age Group	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<1 Year	0.0	1.5	3.7	0.0	2.6	3.0	2.3	0.0	2.1	0.0
1-4 Years	3.1	2.9	1.9	7.0	2.6	6.1	6.8	0.0	0.0	4.1
5-9 Years	3.1	1.5	3.7	0.0	0.0	6.1	4.5	0.0	0.0	0.0
10-19 Years	0.0	5.9	7.4	5.3	10.3	3.0	9.1	0.0	8.5	10.2
20-39 Years	20.3	26.5	14.8	24.6	20.5	24.2	31.8	18.8	19.1	20.4
40-59 Years	40.6	41.2	42.6	36.8	35.9	27.3	29.5	40.6	29.8	36.7
60+ Years	32.8	20.6	25.9	26.3	28.2	30.3	15.9	40.6	40.4	28.6

Figure 12. Percentage of Active TB Cases Born in Canada by Age Group, 2011 to 2020



Active TB Among Populations Born Outside of Canada by Age


Table 16. Active TB Cases Born Outside of Canada by Age Group, 2011 to 2020

Age Group	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<1 Year	0	0	0	0	0	0	0	0	0	0
1-4 Years	0	0	1	1	1	0	1	2	0	0
5-9 Years	1	0	2	0	1	0	0	0	1	0
10-19 Years	6	7	6	7	6	7	11	8	14	16
20-39 Years	61	43	54	59	50	60	62	84	82	88
40-59 Years	58	67	51	70	69	49	57	65	38	52
60+ Years	78	99	107	110	118	95	128	110	129	107

Table 17. Percentage of Active TB Cases Born Outside of Canada by Age Group, 2011 to 2020

Age Group	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<1 Year	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1-4 Years	0.0	0.0	0.5	0.4	0.4	0.0	0.4	0.7	0.0	0.0
5-9 Years	0.5	0.0	0.9	0.0	0.4	0.0	0.0	0.0	0.4	0.0
10-19 Years	2.9	3.2	2.7	2.8	2.4	3.3	4.2	3.0	5.3	6.1
20-39 Years	29.9	19.9	24.4	23.9	20.4	28.4	23.9	31.2	31.1	33.5
40-59 Years	28.4	31.0	23.1	28.3	28.2	23.2	22.0	24.2	14.4	19.8
60+ Years	38.2	45.8	48.4	44.5	48.2	45.0	49.4	40.9	48.9	40.7

Figure 13. Percentage of Active TB Cases Born Outside of Canada by Age Group, 2011 to 2020



Active TB by HIV Status

Table 18. Active TB Cases by Known HIV Status, 2011 to 2020*

HIV Status	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HIV Positive	9	8	8	8	10	5	2	4	4	3
Known HIV Status	210	224	220	262	215	220	253	214	227	237

^{*}Data from 2011-2015 are from iPHIS. Historical case counts have changed slightly over time.


Table 19. Percentage of Active TB Cases by Known HIV Status, 2011 to 2020*

HIV Status	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
% HIV Positive**	4.3	3.6	3.6	3.1	4.7	2.3	0.8	1.9	1.8	1.3
% Known HIV Status	75.8	74.9	80.6	89.4	82.4	86.3	82.1	70.6	72.3	75.2

^{*}Data from 2011-2015 are from iPHIS. Historical case counts have changed slightly over time.

^{**%} HIV positive of those with known HIV status

Figure 14. Percentage of Active TB Cases by Known HIV Status, 2011 to 2020



Active TB by Site of Disease

Table 20. Active TB Cases by Site of Disease, 2011 to 2020

Site of Disease	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Respiratory*	214	242	230	234	216	200	241	233	247	253
Non-respiratory only**	65	57	51	71	72	55	67	70	67	62

^{*}Respiratory includes all cases with at least one respiratory site present (i.e. defined as pulmonary, primary, miliary, and other pulmonary) (see Case Definitions)

Table 21. Percentage of Active TB Cases by Site of Disease, 2011 to 2020


Site of Disease	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Respiratory*	76.7	80.9	81.9	76.7	75.0	78.4	78.2	76.9	78.7	80.3
Non-respiratory only**	23.3	19.1	18.1	23.3	25.0	21.6	21.8	23.1	21.3	19.7

^{*}Respiratory includes all cases with at least one respiratory site present (i.e. defined as pulmonary, primary, miliary, and other pulmonary) (see Case Definitions)

^{**}Non-respiratory only includes all cases with no respiratory site present but at least one non-respiratory site present (see Case Definitions)

^{**}Non-respiratory only includes all cases with no respiratory site present but at least one non-respiratory site present (see Case Definitions)

Figure 15. Percentage of Active TB Cases by Site of Disease, 2011 to 2020



Active TB by Treatment Outcome

Table 22. Active TB Cases by Treatment Outcome, 2011 to 2019

Treatment Summary*	2011	2012	2013	2014	2015	2016	2017	2018	2019
Treatment Completed	224	243	242	252	234	198	248	241	250
- Within 12 Months	182	207	210	212	187	162	212	215	204
- Greater Than 12 Months	42	36	32	40	47	36	36	26	46
Incomplete Treatment	31	38	20	31	36	34	38	33	41
Left Province During Treatment	12	6	4	14	9	18	5	15	17
No Treatment Documented	9	6	4	0	8	2	13	12	4


^{*}Excluding those diagnosed post-mortem

Table 23. Percentage of Active TB Cases by Treatment Outcome, 2011 to 2019

Treatment Summary*	2011	2012	2013	2014	2015	2016	2017	2018	2019
Treatment Completed	81.1	82.9	89.7	84.9	81.6	78.6	81.5	80.0	80.1
- Within 12 Months	65.9	70.6	77.8	71.4	65.2	64.3	69.7	71.4	65.4
- Greater Than 12 Months	15.2	12.3	11.9	13.5	16.4	14.3	11.8	8.6	14.7
Incomplete Treatment	11.2	13.0	7.4	10.4	12.5	13.5	12.5	11.0	13.1
Left Province During Treatment	4.3	2.0	1.5	4.7	3.1	7.1	1.6	5.0	5.4
No Treatment Documented	3.3	2.0	1.5	0.0	2.8	0.8	4.3	4.0	1.3

^{*}Excluding those diagnosed post-mortem

Figure 16. Active TB Cases by Treatment Outcome, 2011 to 2019



Active TB by Reason for Incomplete Treatment


Table 24. Active TB Cases by Reason for Incomplete Treatment, 2011 to 2019

Documented Reason	2011	2012	2013	2014	2015	2016	2017	2018	2019
Died During Treatment	26	24	16	17	27	23	13	24	20
- TB Underlying Cause	6	4	1	3	3	5	3	1	1
- TB Contributed, Not Underlying Cause	10	7	7	9	18	7	8	12	9
- TB Unrelated to Death	9	13	7	3	4	8	2	5	9
- Unknown	1	0	1	2	2	3	0	6	1
Drug Reaction/Intolerance	2	3	2	1	0	2	0	1	4
Lost to Follow Up	1	2	0	6	2	2	7	5	10
Non-Adherence	1	6	0	3	2	2	1	3	1
Other	0	0	0	1	0	0	1	0	5
Unknown	1	3	2	3	5	5	16	0	1

Table 25. Percentage of Active TB Cases by Reason for Incomplete Treatment, 2011 to 2019

Documented Reason	2011	2012	2013	2014	2015	2016	2017	2018	2019
Died During Treatment	83.9	63.2	80.0	54.8	75.0	67.6	34.2	72.7	48.8
- TB Underlying Cause	19.4	10.5	5.0	9.7	8.3	14.7	7.9	3.0	2.4
- TB Contributed, Not Underlying Cause	32.3	18.4	35.0	29.0	50.0	20.6	21.1	36.4	22.0
- TB Unrelated to Death	29.0	34.2	35.0	9.7	11.1	23.5	5.3	15.2	22.0
- Unknown	3.2	0.0	5.0	6.5	5.6	8.8	0.0	18.2	2.4
Drug Reaction/Intolerance	6.5	7.9	10.0	3.2	0.0	5.9	0.0	3.0	9.8
Lost to Follow Up	3.2	5.3	0.0	19.4	5.6	5.9	18.4	15.2	24.4
Non-Adherence	3.2	15.8	0.0	9.7	5.6	5.9	2.6	9.1	2.4
Other	0.0	0.0	0.0	3.2	0.0	0.0	2.6	0.0	12.2
Unknown	3.2	7.9	10.0	9.7	13.9	14.7	42.1	0.0	2.4

Figure 17. Percentage of Active TB Cases by Reason for Incomplete Treatment, 2011 to 2019



Active TB Drug Resistance

Table 26. Active TB Cases by Resistance Type, 2011 to 2020*

Resistance	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
No Resistance	252	279	254	259	233	233	290	282	291	290
Isoniazid Only	23	18	19	25	27	19	16	18	21	23
Rifampin Only	1	0	0	2	0	0	0	2	0	0
Multi-Drug**	1	2	0	7	1	3	2	1	2	2

^{*}Data from 2011-2015 are from iPHIS. Historical case counts have changed slightly over time.

Table 27. Percentage of Active TB Cases by Resistance Type, 2011 to 2020*

Resistance	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
No Resistance	91.0	93.3	93.0	88.4	89.3	91.4	94.2	93.1	92.7	92.1
Isoniazid Only	8.3	6.0	7.0	8.5	10.3	7.5	5.2	5.9	6.7	7.3
Rifampin Only	0.4	0.0	0.0	0.7	0.0	0.0	0.0	0.7	0.0	0.0
Multi-Drug**	0.4	0.7	0.0	2.4	0.4	1.2	0.6	0.3	0.6	0.6

^{*}Data from 2011-2015 are from iPHIS. Historical case counts have changed slightly over time.

^{**}Multi-drug resistance is defined as resistance to both isoniazid and rifampin

^{**}Multi-drug resistance is defined as resistance to both isoniazid and rifampin

Figure 18. Active TB Cases by Resistance Type, 2011 to 2020





Figure 19. Percentage of Active TB Cases by Resistance Type, 2011 to 2020



Latent TB Treatment

Latent tuberculosis infection (LTBI) is a clinical diagnosis in which an individual is suspected to have the non-infectious or dormant phase of TB. The recommendation to treat LTBI is based on a clinical assessment of the patient balancing the risks for progression to active TB against the risks associated with treatment. Not everyone with LTBI is offered or needs treatment.

Here we report on LTBI treatment outcomes for treatment started in 2019 due to the potential extended duration of treatment and follow up that could contribute to delays in reporting. Any LTBI treatment starts not documented in Panorama (e.g. treatment given in federal and provincial correctional facilities) would not be captured in this report (see Technical Appendix and Case Definitions). Note that clients receiving primary prophylaxis are not reported here.

In 2019, 766 clients started LTBI treatment. A total of 76.1% (583 clients) of those starting treatment in 2019 successfully completed treatment, with 75.8% (581 clients) completing treatment within 12 months and only 0.3% (2 clients) taking more than 12 months to complete treatment (Table 29; Figure 20). Since 2011, the proportion of clients that have completed LTBI treatment within 12 months has increased.

Of those starting treatment in 2019, 68.4% (524 clients) were born outside of Canada, 20.9% (160 clients) were Canadian born, and 10.7% (82 clients) had an unknown country of birth or had missing data (Table 31; Figure 21). In 2019, 38.4% (294 clients) were 40-59 years of age, 29.2% (224 clients) were 60 years of age and older, and 27.0% (207 clients) were 20-39 years of age (Table 33). Overall, LTBI treatment was primarily documented in the three oldest age groups (Figure 22).

LTBI Treatment


Table 28. Clients Started on LTBI Treatment by Treatment Outcome, 2011 to 2019

Treatment Summary	2011	2012	2013	2014	2015	2016	2017	2018	2019
Treatment Completion Within 12 Months	542	601	599	625	583	447	493	611	581
Treatment Completion Greater Than 12 Months	17	9	7	10	16	6	10	5	2
Incomplete Treatment	218	219	195	163	260	222	183	214	183

Table 29. Percentage of Clients Started on LTBI Treatment by Treatment Outcome, 2011 to 2019

Treatment Summary	2011	2012	2013	2014	2015	2016	2017	2018	2019
Treatment Completion Within 12 Months	69.8	72.5	74.8	78.3	67.9	66.2	71.9	73.6	75.8
Treatment Completion Greater Than 12 Months	2.2	1.1	0.9	1.3	1.9	0.9	1.5	0.6	0.3
Incomplete Treatment	28.1	26.4	24.3	20.4	30.3	32.9	26.7	25.8	23.9

Figure 20. Percentage of Clients Started on LTBI Treatment by Treatment Outcome, 2011 to 2019



LTBI Treatment by Country of Birth

Table 30. Clients Started on LTBI Treatment by Country of Birth, 2011 to 2019

Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019
Born Outside of Canada	496	577	570	597	647	506	487	636	524
Canadian Born	248	230	212	189	195	148	153	148	160
Missing*	33	22	19	12	17	21	46	46	82


^{*}Unknown or undocumented country of birth

Table 31. Percentage of Clients Started on LTBI Treatment by Country of Birth, 2011 to 2019

Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019
Born Outside of Canada	63.8	69.6	71.2	74.8	75.3	75.0	71.0	76.6	68.4
Canadian Born	31.9	27.7	26.5	23.7	22.7	21.9	22.3	17.8	20.9
Missing*	4.2	2.7	2.4	1.5	2.0	3.1	6.7	5.5	10.7

^{*}Unknown or undocumented country of birth

Figure 21. Percentage of Clients Started on LTBI Treatment by Country of Birth, 2011 to 2019



LTBI Treatment by Age

Table 32. Clients Started on LTBI Treatment by Age Group in BC, 2011 to 2019

Age Group*	2011	2012	2013	2014	2015	2016	2017	2018	2019
<1 Year	1	1	0	1	1	3	1	2	1
1-4 Years	13	3	13	9	12	8	9	7	9
5-9 Years	13	9	16	11	13	4	10	8	9
10-19 Years	29	32	41	43	36	17	13	38	22
20-39 Years	271	246	227	232	242	199	185	235	207
40-59 Years	313	382	343	335	342	262	271	300	294
60+ Years	137	156	161	167	213	182	197	240	224

^{*}Age at time of LTBI treatment


Table 33. Percentage of Clients Started on LTBI Treatment by Age Group in BC, 2011 to 2019

Age Group*	2011	2012	2013	2014	2015	2016	2017	2018	2019
<1 Year	0.1	0.1	0.0	0.1	0.1	0.4	0.1	0.2	0.1
1-4 Years	1.7	0.4	1.6	1.1	1.4	1.2	1.3	0.8	1.2
5-9 Years	1.7	1.1	2.0	1.4	1.5	0.6	1.5	1.0	1.2
10-19 Years	3.7	3.9	5.1	5.4	4.2	2.5	1.9	4.6	2.9
20-39 Years	34.9	29.7	28.3	29.1	28.2	29.5	27.0	28.3	27.0
40-59 Years	40.3	46.1	42.8	42.0	39.8	38.8	39.5	36.1	38.4
60+ Years	17.6	18.8	20.1	20.9	24.8	27.0	28.7	28.9	29.2

^{*}Age at time of LTBI treatment

60+

Figure 22. Total Clients Started on LTBI Treatment by Age Group in BC, 2011 to 2019



TB Contact Tracing

Contact tracing is an important public health intervention that involves identifying individuals who may be at risk of having TB infection or active TB disease as a result of having shared air space with an active TB case. Not all person-to-person contact is equivalent; contacts are classified and prioritized based on the type of TB (in some cases), duration of contact, and contact risk factors. This section of the report provides data on contacts of known active TB cases diagnosed in BC and those contacts residing in BC at time of investigation (i.e. contacts identified as part of federally managed airplane screening, contacts of non-resident cases, or contacts residing outside of BC are not included). Anonymous contacts are not included in this report. Note that contacts and screenings – specifically contacts with negative screening results – are underreported in Panorama.

Among the 253 respiratory active TB cases (primary, pulmonary, miliary, and other pulmonary) in 2020, a total of 1300 unique contacts were identified in Panorama (Table 34). This corresponds to a mean of 5.1 contacts per respiratory active TB case (median=3.0), a decrease compared to a mean of 8.7 (median = 3.0) observed in 2019. The maximum number of contacts associated with a single case in 2020 was 44 – this figure has ranged from 92 to 421 contacts from 2011 to 2019. Of the contacts reported in 2020, 34.8% (453 contacts) occurred in those 20-39 years of age, 27.4% (356 contacts) occurred in those 40-59 years of age, and 17.8% (231 contacts) occurred in those 60 years of age and older (Table 36; Figure 23). In 2020, 47.8% (621 contacts) of contacts were born outside of Canada, 38.5% (500 contacts) were Canadian born, and 13.8% (179 contacts) had no country of birth documented (Table 38; Figure 24).

Overall, a decrease was observed among reported contacts in 2020 which may be due to the COVID-19 pandemic and the reallocation of public health resources. While TB contact tracing was still performed for respiratory active TB cases throughout the pandemic, in many jurisdictions it was primarily focused on high priority contacts before this was expanded, and ultimately returned to normal procedures. As a result, contacts that would have been identified and reported pre-pandemic may not be represented in the 2020 data.

Contacts per Case

Table 34. Mean, Median, Max, and Total Number of Contacts* Reported for Respiratory Active TB Case in BC, 2011 to 2020**

Measure	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Mean	21.4	22.4	19.9	10.3	10.3	9.4	10.3	10.2	8.7	5.1
Median	9.5	13.0	11.0	5.0	6.0	6.0	5.0	4.0	3.0	3.0
Max	421	236	182	97	99	92	234	98	203	44
Total	3928	5138	4184	1963	1864	1890	2476	2368	2154	1300

^{*}Excludes anonymous contacts

^{**} Data from 2011-2015 are from iPHIS. Historical counts have changed slightly over time.

Contacts by Age

Table 35. Contacts of Respiratory Active TB Cases by Age Group in BC, 2011 to 2020*

Age Group**	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<1 Year	9	16	29	6	20	31	21	26	18	24
1-4 Years	71	114	98	69	104	116	157	91	105	55
5-9 Years	142	164	150	57	66	87	68	76	45	53
10-19 Years	241	359	337	151	84	111	134	156	298	128
20-39 Years	1257	1599	1172	624	537	579	756	883	667	453
40-59 Years	1402	1883	1538	712	665	573	814	792	687	356
60+ Years	758	975	828	318	366	389	526	344	334	231
Unknown	48	28	32	26	22	4	0	0	0	0

^{*}Data from 2011-2015 are from iPHIS. Historical case counts have changed slightly over time.

Table 36. Percentage of Contacts of Respiratory Active TB Cases by Age Group in BC, 2011 to 2020*


Age Group**	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<1 Year	0.2	0.3	0.7	0.3	1.1	1.6	0.8	1.1	0.8	1.8
1-4 Years	1.8	2.2	2.3	3.5	5.6	6.1	6.3	3.8	4.9	4.2
5-9 Years	3.6	3.2	3.6	2.9	3.5	4.6	2.7	3.2	2.1	4.1
10-19 Years	6.1	7.0	8.1	7.7	4.5	5.9	5.4	6.6	13.8	9.8
20-39 Years	32.0	31.1	28.0	31.8	28.8	30.6	30.5	37.3	31.0	34.8
40-59 Years	35.7	36.6	36.8	36.3	35.7	30.3	32.9	33.4	31.9	27.4
60+ Years	19.3	19.0	19.8	16.2	19.6	20.6	21.2	14.5	15.5	17.8
Unknown	1.2	0.5	0.8	1.3	1.2	0.2	0.0	0.0	0.0	0.0

^{*}Data from 2011-2015 are from iPHIS. Historical case counts have changed slightly over time.

^{**}Age at time of source case diagnosis

^{**}Age at time of source case diagnosis

Figure 23. Percentage of Contacts of Respiratory Active TB Cases by Age Group in BC, 2011 to 2020



Contacts by Country of Birth

Table 37. Contacts of Respiratory Active TB Cases by Country of Birth in BC, 2011 to 2020*

Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Born Outside of Canada	1143	1525	1604	888	906	768	972	1174	755	621
Canadian Born	1722	2635	1701	778	769	790	985	919	922	500
Missing**	1063	978	879	297	189	332	519	275	477	179

^{*}Data from 2011-2015 are from iPHIS. Historical counts have changed slightly over time.

Table 38. Percentage of Contacts of Respiratory Active TB Cases by Country of Birth in BC, 2011 to 2020*


Country of Birth	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Born Outside of Canada	29.1	29.7	38.3	45.2	48.6	40.6	39.3	49.6	35.1	47.8
Canadian Born	43.8	51.3	40.7	39.6	41.3	41.8	39.8	38.8	42.8	38.5
Missing**	27.1	19.0	21.0	15.1	10.1	17.6	21.0	11.6	22.1	13.8

^{*}Data from 2011-2015 are from iPHIS. Historical counts have changed slightly over time.

^{**}Unknown or undocumented country of birth

^{**}Unknown or undocumented country of birth

Figure 24. Percentage of Contacts of Respiratory Active TB Cases by Country of Birth in BC, 2011 to 2020



020 Contact Tracing

Contact Tracing Cascade of Care

The contact tracing cascade of care provides insights on activities aimed to end the cycle of transmission through prompt assessment and treatment of infected contacts. It enables better understanding of where losses are occurring among the follow-up activities and may inform areas where public health interventions can be strengthened. See Case Definitions for indicator definitions.

This report presents data on the cascade of care for contacts of respiratory active TB cases in BC aged 5 years and older, with indicators stratified by time after source case diagnosis (12, 26, and 52 weeks). Additionally, total completion is reported at 2 years post source case diagnosis for all indicators except for secondary case identification that may be reported up to the date of data extraction (see Technical Appendix). Active TB cases less than 5 years of age — and any associated contacts — were excluded as they typically represent recent transmission and the approach here is to identify the source case rather than to contact trace (i.e. reverse contact investigation). Due to the potential extended duration of treatment and follow up that could contribute to delays in reporting, the contact cascade of care is presented for contacts of source cases diagnosed in 2017, 2018, and 2019.

Of respiratory active TB cases aged 5 years and older diagnosed in 2019, there were 2154 contacts identified among whom 88.3% (1903 contacts) completed an initial assessment, 15.5% (334 contacts) had a positive IGRA or TST screen (a proxy for LTBI), and only 0.6% (14 contacts) were identified as secondary cases (Table 42; Figure 26). The vast majority of contacts (85.9%, 1850 contacts) completed an initial assessment within 26 weeks of the source case diagnosis in 2019, which is consistent with previous years (Table 40; Figure 25). Of the 334 total contacts who had a positive screen, 37.4% (125 contacts) started and completed LTBI treatment. Across all years, and once contacts with a positive screen have been identified, treatment initiation and completion have been steps where the greatest drops in the cascade were observed. The data has shown that it can take 52 weeks or more post source case diagnosis to get contacts through treatment, underscoring the unique challenges inherent in TB prevention and care.

Table 39. Contact Tracing Indicators Among Contacts of Respiratory Active TB Cases Aged 5 Years and Older at 12 Weeks After Source Case Diagnosis in BC, 2017 to 2019

	Count			Percentage^		
Indicator	2017	2018	2019	2017	2018	2019
Number of contacts	2470	2368	2154	100.0	100.0	100.0
Started initial assessment	1808	1729	1499	73.2	73.0	69.6
Completed initial assessment*	1771	1651	1416	71.7	69.7	65.7
- IGRA	99	60	58	4.0	2.5	2.7
- TST	1332	1260	1075	53.9	53.2	49.9
- X-Ray	340	331	283	13.8	14.0	13.1
Secondary cases	7	2	4	0.3	0.1	0.2
Positive screen**	285	249	176	11.5	10.5	8.2
- IGRA	25	26	22	1.0	1.1	1.0
- TST	260	223	154	10.5	9.4	7.1
Started treatment	24	24	22	1.0	1.0	1.0
Completed treatment	0	0	0	0.0	0.0	0.0

^{*}Using earliest screening date

^{**}For contacts with both IGRA and TST positive results, the IGRA date and result was used

[^]Percentage of total contacts reported

Table 40. Contact Tracing Indicators Among Contacts of Respiratory Active TB Cases Aged 5 Years and Older at 26 Weeks After Source Case Diagnosis in BC, 2017 to 2019

	Count			Percentage^			
Indicator	2017	2018	2019	2017	2018	2019	
Number of contacts	2470	2368	2154	100.0	100.0	100.0	
Started initial assessment	2213	2160	1951	89.6	91.2	90.6	
Completed initial assessment*	2142	2108	1850	86.7	89.0	85.9	
- IGRA	124	78	75	5.0	3.3	3.5	
- TST	1630	1585	1417	66.0	66.9	65.8	
- X-Ray	388	445	358	15.7	18.8	16.6	
Secondary cases	10	7	6	0.4	0.3	0.3	
Positive screen**	380	369	288	15.4	15.6	13.4	
- IGRA	79	70	70	3.2	3.0	3.2	
- TST	301	299	218	12.2	12.6	10.1	
Started treatment	77	66	81	3.1	2.8	3.8	
Completed treatment	4	8	7	0.2	0.3	0.3	

^{*}Using earliest screening date

^{**}For contacts with both IGRA and TST positive results, the IGRA date and result was used

[^]Percentage of total contacts reported

Table 41. Contact Tracing Indicators Among Contacts of Respiratory Active TB Cases Aged 5 Years and Older at 52 Weeks After Source Case Diagnosis in BC, 2017 to 2019

	Count			Percentage^			
Indicator	2017	2018	2019	2017	2018	2019	
Number of contacts	2470	2368	2154	100.0	100.0	100.0	
Started initial assessment	2261	2226	1992	91.5	94.0	92.5	
Completed initial assessment*	2189	2175	1891	88.6	91.8	87.8	
- IGRA	129	95	77	5.2	4.0	3.6	
- TST	1661	1609	1444	67.2	67.9	67.0	
- X-Ray	399	471	370	16.2	19.9	17.2	
Secondary cases	13	9	7	0.5	0.4	0.3	
Positive screen**	416	389	319	16.8	16.4	14.8	
- IGRA	106	88	99	4.3	3.7	4.6	
- TST	310	301	220	12.6	12.7	10.2	
Started treatment	139	118	132	5.6	5.0	6.1	
Completed treatment	53	59	82	2.1	2.5	3.8	

^{*}Using earliest screening date

^{**}For contacts with both IGRA and TST positive results, the IGRA date and result was used

[^]Percentage of total contacts reported

Table 42. Contact Tracing Indicators Among Contacts of Respiratory Active TB Cases Aged 5 Years and Older at Total Completion[†] After Source Case Diagnosis in BC, 2017 to 2019

	Count			Percentage^		
Indicator	2017	2018	2019	2017	2018	2019
Number of contacts	2470	2368	2154	100.0	100.0	100.0
Started initial assessment	2278	2237	2003	92.2	94.5	93.0
Completed initial assessment*	2206	2187	1903	89.3	92.4	88.3
- IGRA	129	98	81	5.2	4.1	3.8
- TST	1673	1613	1448	67.7	68.1	67.2
- X-Ray	404	476	374	16.4	20.1	17.4
Secondary cases	18	13	14	0.7	0.5	0.6
Positive screen**	422	398	334	17.1	16.8	15.5
- IGRA	109	97	112	4.4	4.1	5.2
- TST	313	301	222	12.7	12.7	10.3
Started treatment	158	130	152	6.4	5.5	7.1
Completed treatment	111	93	125	4.5	3.9	5.8

^{*}Using earliest screening date


^{**}For contacts with both IGRA and TST positive results, the IGRA date and result was used

[^]Percentage of total contacts reported

[†]Total completion is reported at 2 years post source case diagnosis for all indicators except for secondary case identification, which may be reported up to the date of data extraction.


2020 Contact Tracing

Figure 25. Contact Tracing Indicators Among Contacts of Respiratory Active TB Cases Aged 5 Years and Older by Completion Time After Source Case Diagnosis in BC, 2019



020 Contact Tracing

Figure 26. Contact Tracing Indicators Among Contacts of Respiratory Active TB Cases in BC Aged 5 Years and Older at Total Completion After Source Case Diagnosis, 2017 to 2019



Contributors

Epidemiology & Surveillance Team, Clinical Prevention Services

Arina Zamanpour, Epidemiologist
Fay Hutton, Surveillance Analyst
Wrency Tang, Surveillance Analyst
Dr. Jason Wong, Surveillance Lead & Medical Director
Dr. Victoria Cook, Medical Lead

We would like to acknowledge the contributions of our many partners who without their support this report would not have been possible.

- The BC Centre for Disease Control (BCCDC) TB Services staff for time spent entering provincial data and assisting with reporting.
- Physicians, health care providers, and public health staff in BC for taking the time and effort to collect and submit provincial TB data.
- The BCCDC Public Health Laboratory staff for collecting and compiling TB and HIV requisition data.
- Designated public health nurses in the Health Service Delivery Areas for data collection as part of follow-up to persons testing positive for TB.
- The BCCDC TB Services Health Registry Clerk and the Island TB Program staff for their help with active TB data entry and remediation.
- Sunny Mak from the BCCDC for creating the map of active TB rates by Health Service Delivery Areas.
- Tuberculosis Section, Centre for Communicable Disease and Infection Control, Public Health Agency of Canada (PHAC) for providing the annual rates of active TB in Canada.

$\frac{1020}{1000}$ Technical Appendix

Technical Appendix

- All TB surveillance data comes from Panorama Public Health Solution for Disease Surveillance and Management, unless otherwise noted. The BCCDC TB Services commenced using Panorama on March 12, 2016, with data conversion from the previous Integrated Public Health Information System (iPHIS). Minor differences in the aggregate counts may be seen if comparing annual report data to that found in iPHIS due to data conversion from iPHIS to Panorama. Numbers in this report are subject to change due to data clean up and possible late reporting.
- All geographic breakdowns reflect place of residence at time of diagnosis or time of treatment (including temporary residence). Subsequent movement is not reflected in this report.
- All active TB, LTBI, contact tracing, and laboratory data were extracted from Panorama on July 21, 2022.
- Active TB is rare in BC. Rates or percentages over time for some indicators may reflect minor differences in small numbers, and not meaningful changes in the underlying disease process.
- Active TB case totals may differ from those reported by PHAC. Among temporary residents (visitors, students, and people granted work permits) and undocumented foreign nationals who are in Canada, PHAC includes only those cases that started treatment in BC in provincial totals. However, the BCCDC includes all cases who have been diagnosed or received treatment in BC in provincial totals – regardless of where the treatment initially began.
- This report includes HIV status and co-infection reliant on testing or self-reporting done
 at time of active TB diagnosis. Accordingly, active TB cases living with HIV that were not
 tested for HIV or did not self-report their HIV diagnosis at the time of TB diagnosis,
 would not be represented in this data. For that reason, the percentage of known HIV
 status among TB cases is believed to be an underestimate due to incomplete
 ascertainment of screening tests and HIV/AIDS case reports.
- For active TB cases, HIV status and drug resistance data from 2011 to 2015 were not readily accessible for reporting out of Panorama. Thus, case counts and proportions for this period were obtained from historical iPHIS data⁷ to enable assessment of trends. Historic case counts and proportions should be interpreted with caution as they have changed slightly over time.

- LTBI treatment data presented in this report is from Panorama only. Any LTBI treatment data not documented in Panorama (e.g. treatment given in federal and provincial correctional facilities) would not be represented here.
- The contact information presented in this report includes only contacts of active TB cases (i.e. source cases) identified in BC, who were residing in BC at time of investigation, and who were linked to a source case in Panorama. The data does not include contacts identified as part of federal airplane screening, contacts of sources cases not identified in BC, or anonymous contacts. Regions have separate databases for contact investigations that may not be reported in Panorama. As a result, the data presented does not reflect the full workload of contact tracing teams. Trends in the number of contacts are affected by the circumstances of each case and differences in the collection, entry and reporting of contact data. Provincial workflows for contact tracing and contact data entry changed in 2013, and again in 2016 with the implementation of Panorama, and should be considered when interpreting the provincial surveillance data presented here.
- Contact data from 2011 to 2015 were not readily accessible for reporting out of Panorama. Thus, counts and proportions for this period were obtained from historical iPHIS data⁷ to enable assessment of trends. Historic counts and proportions should be interpreted with caution.
- The contact tracing cascade of care indicators are based on screening, diagnosis, and treatment completed after the source case was diagnosed, and does not capture contact tracing activities initiated before the source case was diagnosed. Total completion is reported at 2 years post source case diagnosis for all indicators except for secondary case identification (Indicator 3), which may be reported up to the date of data extraction (i.e. any time after source case diagnosis). Each indicator (i.e. step) in the cascade is a subset of the previous, except for secondary cases (Indicator 3) which is based on all contacts (i.e. denominator).

Case Definitions

A. Active TB

Detection and confirmation of *Mycobacterium tuberculosis* complex or clinical presentation compatible with active tuberculosis disease, excluding tuberculosis re-treatment within 6 months.

Laboratory confirmed case

Cases with *Mycobacterium tuberculosis* complex isolated by culture from a clinical specimen – specifically *M. tuberculosis*, *M. africanum*, *M. canetti*, *M. caprae*, *M. microti*, *M. pinnipedii*, M. *orygis*, or *M. bovis* (excluding *M. bovis* BCG strain).

Clinically confirmed case

In the absence of confirmation by culture proof, cases clinically compatible with active tuberculosis disease such as:

- Chest x-ray changes compatible with active tuberculosis;
- Clinical symptoms and/or signs of non-respiratory tuberculosis (meninges, bone, kidney, peripheral lymph nodes, etc.);
- Histopathologic or post-mortem evidence of active tuberculosis;
- Favorable response to therapeutic trial of antituberculosis drugs.

Re-treatment exclusion:

A re-treatment case of tuberculosis is a case that has both current active tuberculosis disease and historic documentation of previous active disease. Where re-treatment commences within 6 months after the end of treatment for previously active tuberculosis, the re-treatment is not counted as a new case of active tuberculosis. This is consistent with the Public Health Agency of Canada's case definition of re-treatment.

HIV Screening and Co-infection

HIV co-infection

- Active TB cases with a positive HIV test result at the time of TB diagnosis;
- Active TB cases with self-reported HIV diagnosis at the time of TB diagnosis.

Known HIV status

- Active TB cases with a positive or negative HIV test result at the time of TB diagnosis;
- Active TB cases with self-reported HIV diagnosis at the time of TB diagnosis.

Drug Resistance

Active cases are classified as resistant to rifampin, isoniazid, or both (i.e. multi-drug resistant). Resistance to other TB medications is not reported here.

B. Site of Disease

Since the implementation of Panorama, tuberculosis sites of disease were rationalized into a list of body sites used and recognized by tuberculosis clinicians. The new tuberculosis sites are similar to many sites in ICD-9 tuberculosis disease coding.

This report divides tuberculosis into respiratory and non-respiratory based on site of disease. Tuberculosis is classified as respiratory if at least one respiratory site is present. Tuberculosis is considered non-respiratory if no respiratory site is present but at least one non-respiratory site is present.

Respiratory sites

- primary tuberculosis
- pulmonary tuberculosis
- pneumonia tuberculosis
- miliary tuberculosis
- pleurisy tuberculosis
- isolated tracheal or bronchial tuberculosis
- laryngitis tuberculosis (excluding esophageal tuberculosis)
- cavitation of lung tuberculosis
- intrathoracic lymph node tuberculosis
- nose or sinus tuberculosis.

Non-respiratory sites

- meningeal tuberculosis
- central nervous system tuberculosis
- meningeal or central nervous system tuberculosis
- peripheral lymph node tuberculosis
- spinal column tuberculosis

- knee tuberculosis
- bone tuberculosis
- joint tuberculosis
- kidney tuberculosis
- genitourinary tuberculosis
- skin and subcutaneous tuberculosis
- ervthema nodosum tuberculosis
- eye tuberculosis
- ear tuberculosis
- thyroid gland tuberculosis
- adrenal gland tuberculosis
- spleen tuberculosis
- other organ tuberculosis (excluding respiratory)

C. Latent Tuberculosis Infection (LTBI)

The clinical definition for LTBI is based on a complex mix of demographic characteristics and the presence of co-morbidities. As a surrogate, we report on clients who have documentation of LTBI treatment initiation in Panorama, which is likely an underestimate of the actual number of persons with LTBI.

D. Treatment Completion

For the purposes of this report, treatment completion for active TB and LTBI documented in Panorama is defined as the following:

Treatment Completed: A treatment start date, treatment end date, and treatment status reported as "Completed-satisfactory". The length of treatment is calculated based on the treatment start date and treatment end date.

Incomplete Treatment: A treatment start date, treatment end date, and treatment status other than "Completed-satisfactory" (i.e. "Completed-unsatisfactory", "Incomplete", "Other", "Unknown"), or no treatment end date is documented.

Left Province During Treatment: Includes transfers within Canada and outside of Canada.

No Treatment Documented: No treatment start date is documented.

E. TB Contact Tracing Cascade of Care Indicators

Each indicator (i.e. step) in the cascade is a subset of the previous, except for secondary cases (Indicator 3) which is based on all contacts (i.e. denominator). Indicators are reported based on the year the source case was diagnosed.

Denominator - Number of contacts: Number of unique contacts linked to respiratory active TB cases aged 5 years and older in BC, excluding contacts residing outside of BC at time of investigation. For contacts who were exposed to more than one source case in the reporting year, the earliest exposure for the contact (i.e. based on source case diagnosis date) was used.

Indicator 1 - Started initial assessment: Number of contacts who started any of the following after the source case diagnosis date: Tuberculin Skin Test (TST) planted, Interferon-Gamma Release Assay (IGRA) test, or X-Ray. For contacts who received more than one type of screen, the earliest screening date was used.

Indicator 2 - Completed initial assessment: Number of contacts who completed any of the following after the source case diagnosis date: TST read with valid result, IGRA test with valid result, or X-Ray. For contacts who received more than one type of screen, the earliest screening date was used.

Indicator 3 - Secondary cases: Number of total contacts (i.e. denominator) diagnosed with confirmed or clinical active TB after the source case diagnosis date.

Indicator 4 - Positive screen: Number of contacts — who are not secondary cases — with any of the following after the source case diagnosis date: a reactive IGRA, or a positive TST (without a subsequent non-reactive IGRA). For contacts with multiple TST or IGRA results, the earliest screening date was used. For contacts with both IGRA and TST positive results, the IGRA date and result was used. This is a proxy measure for clients with LTBI.

Indicator 5 - Started treatment: Number of contacts with a positive screen and a treatment start date after the source case diagnosis date.

Indicator 6 - Completed treatment: Number of contacts with a treatment start date, treatment end date, and treatment status reported as "Completed-satisfactory" after the source case diagnosis date.

Data Sources

Panorama

Data presented in this report was extracted from Panorama. The BCCDC TB Services commenced using Panorama on March 12, 2016, with data conversion from the previous Integrated Public Health Information System (iPHIS). Some iPHIS-converted data could not be readily extracted for reporting in Panorama (e.g. drug resistance, HIV status and co-infection, contact follow-up), and these data were obtained from iPHIS using the 2015 TB Annual Report to produce trend lines for this reporting period (this is indicated throughout the report in footnotes). Historic case counts may have changed since the data was reported in 2015 (due to data cleanup and late reporting); therefore, these trends should be interpreted with caution.

Population Data

Population data and associated rates for the general BC population, age, gender, regional health authority, and health service delivery area were based on the Population Estimates released by BC Stats.

Population data and associated rates for those born outside of Canada and Canadian born individuals were estimated from the 2011 and 2016 Census Program, conducted by Statistics Canada. Estimates for those born outside of Canada were calculated as the sum of "immigrant" and "non-permanent resident" counts, while Canadian born estimates were obtained from the "non-immigrant" counts. For population estimates for the years between the quinquennial censuses, this method assumes proportional annual changes in the population until the following census.

Additional Notes Classification of Health Region

Cases are assigned to health regions (i.e. Health Authority of Health Service Delivery Area (HSDA)) by residence. If residence is unknown, the case is assigned to the health region where the individual was diagnosed or screened.

References

- 1. Government of Canada. Notifiable Diseases Online. 2022 [cited 2022]. Available from: https://diseases.canada.ca/notifiable/charts?c=pl
- BC Centre for Disease Control. BC Tuberculosis Strategic Plan 2012-2021 Final Report
 [Internet]. 2021 [cited 2022]. Available from: http://www.bccdc.ca/resourcegallery/Documents/Statistics%20and%20Research/Publications/TB/TBSC%20Final%20Re
 port.pdf#:~:text=The%20BC%20Strategic%20Plan%20for%20Tuberculosis%20Prevention
 %2C%20Treatment,state-of-theart%20treatment%20and%20care%20if%20infection%20should%20occur.
- World Health Organization. The End TB Strategy Technical Report [Internet]. 2015 [cited 2022]. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19
- 4. World Health Organization. Countries [Internet]. 2022 [cited 2022]. Available from: https://www.who.int/countries/
- 5. Lönnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ, Lange C. Tuberculosis in migrants in low-incidence countries: Epidemiology and intervention entry points. Int J Tuberc Lung Dis. 2017; 21(6): 624-637. doi: 10.5588/ijtld.16.0845
- 6. World Health Organization. Global Tuberculosis Report 2022 [Internet]. 2022 [cited 2022]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
- 7. BC Centre for Disease Control. TB in British: Columbia: Annual Surveillance Report 2015 [Internet]. 2016 [cited 2022]. Available from: http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Statistics%20and%20Reports/TB/TB_Annual_Report_2015.pdf
- 8. Statistics Canada. Census Program [Internet]. 2019 [cited 2022]. Available from: https://www12.statcan.gc.ca/census-recensement/index-eng.cfm